Hematologic Oncology

A new study has identified a clinically and biologically distinct subgroup of diffuse large B-cell lymphoma tumors.

A study looked at whether survivorship care plans were able to enhance patients' knowledge and adherence to physician recommendations.

Researchers analyzed a new recurrent BCL2 mutation appearing in a cohort of patients with CLL-type progressions treated with venetoclax.

Researchers examined adding daratumumab to standard of care in newly diagnosed transplant-ineligible myeloma patients.

Researchers uncovered distinct clinical characteristics in relapsed/refractory multiple myeloma patients receiving proteasome inhibitors.

Leukemia cells show sensitivity to restriction of BCL2 and BTK with the combination of venetoclax and ibrutinib.

Researchers studied clonal hematopoiesis of indeterminate potential (CHIP) as a way to assess risk for increased mortality in lymphoma patients.

Researchers developed an enhanced genomic model combining clinical factors and select gene mutations in order to better predict survival in patients with DLBCL who were administered first-line R-CHOP.

Researchers analyzed double vs single autologous stem cell transplantation in patients with newly diagnosed multiple myeloma, after previous conflicting results.

This study looked at the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering multiple myeloma.

Allogeneic hematopoietic stem cell transplantation could improve outcomes of elderly patients with acute myeloid leukemia.

Researchers used high throughput drug screening on leukemic stem cells to determine drug resistance and sensitivity in acute myeloid leukemia patients.

A study investigates whether R-CHOP is a viable first-line treatment for patients with advanced follicular lymphoma.

A phase III study looks at the efficacy and safety of rituximab biosimilar CT-P10 in patients with follicular lymphoma.

Researchers discovered clinical and experimental evidence that calls into question the widely held notion that LSCs preferentially outlive chemotherapy.

Stephanie Jackson, MSN, RN speaks with Cancer Network about the role oncology nurses play in managing patients with hematologic malignancies who are undergoing CAR T-cell therapy.

The ground-breaking study, led by the Leukemia & Lymphoma Society, is evaluating several novel targeted therapies for acute myeloid leukemia.

In this article, we describe the considerations for the use of BTK inhibitors in lymphoid malignancies from the perspective of an oncology pharmacist.

Does patient race play a role in the efficacy of monoclonal antibodies in multiple myeloma?

The ELOQUENT-3 trial looks at how the of addition of elotuzumab to pomalidomide and dexamethasone impacts patient outcomes in multiple myeloma. 

Cancer patients in England will receive a new game-changing therapy treatment under the first negotiated deal of its kind struck in Europe.

An inflammation marker was associated with several unfavorable characteristics in diffuse large B-cell lymphoma.

New research evaluated whether symptomatic indolent follicular lymphoma requires new long-term therapy after first-line rituximab without chemotherapy.

A study shows that lower doses of ibrutinib after a full-dose cycle may be enough for continued biological activity.

Long-term data from the phase III HELIOS trial indicates ibrutinib plus bendamustine and rituximab improve survival outcomes in CLL patients.

Evaluating the prognostic value of PET-CT responses after first-line immunochemotherapy in follicular lymphoma.

Dr. Ian Flinn spoke with Cancer Network about incorporating the newest approved therapies for the management of CLL.

FDA approves once-weekly carfilzomib/dexamethasone combo for relapsed or refractory multiple myeloma.

A study shows thalidomide-based treatment carries risk, but could be an option for certain multiple myeloma patients.

The research, published in JAMA Oncology, evaluates survival outcomes of a second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion.